MIRA Pharmaceuticals
MIRA
3 hedge funds and large institutions have $3.72K invested in MIRA Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSB
Sandy Spring Bank
Olney,
Maryland
|
+$3.86K |
| 2 |
JP Morgan Chase
New York
|
+$571 |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$143 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSB
1
Sandy Spring Bank
Olney,
Maryland
| $3.14K | +$3.86K | +675 | New |
|
|
2
JP Morgan Chase
New York
| $465 | +$571 | +100 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $116 | +$143 | +25 | New |
|
MIRA Hedge Fund Activity: Q3 2023 in Review
3 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q3 2023, worth a combined $3.72K.
Buyers outnumbered sellers: 3 funds opened new MIRA positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Sandy Spring Bank, opening a new position worth an estimated $3.86K.
- 3 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $3.72K of MIRA Pharmaceuticals stock for Q3 2023.
- 3 funds opened new MIRA Pharmaceuticals positions in Q3 2023 and 0 closed out, a net change of +3 holders.
- The largest MIRA Pharmaceuticals buyer in Q3 2023 was Sandy Spring Bank, an estimated $3.86K added.
Based on aggregated 13F filings for Q3 2023.